SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/31/17 Ziopharm Oncology Inc 10-Q 6/30/17 53:3.8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 615K 2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K 11: R1 Document and Entity Information HTML 38K 12: R2 Balance Sheets HTML 98K 13: R3 Balance Sheets (Parenthetical) HTML 47K 14: R4 Statements of Operations HTML 48K 15: R5 Statements of Stockholders' Deficit HTML 60K 16: R6 Statements of Stockholders' Deficit HTML 18K (Parenthetical) 17: R7 Statements of Cash Flows HTML 97K 18: R8 Statements of Cash Flows (Parenthetical) HTML 18K 19: R9 Business HTML 30K 20: R10 Financings HTML 20K 21: R11 Summary of Significant Accounting Policies HTML 27K 22: R12 Fair Value Measurements HTML 45K 23: R13 Net Loss per Share HTML 28K 24: R14 Commitments and Contingencies HTML 104K 25: R15 Related Party Transactions HTML 36K 26: R16 Stock-Based Compensation HTML 56K 27: R17 Preferred Stock HTML 34K 28: R18 Derivative Financial Instruments HTML 35K 29: R19 Summary of Significant Accounting Policies HTML 27K (Policies) 30: R20 Fair Value Measurements (Tables) HTML 36K 31: R21 Net Loss per Share (Tables) HTML 25K 32: R22 Stock-Based Compensation (Tables) HTML 58K 33: R23 Derivative Financial Instruments (Tables) HTML 36K 34: R24 Business - Additional Information (Detail) HTML 21K 35: R25 Financings - Additional Information (Detail) HTML 25K 36: R26 Assets and Liabilities Measured at Fair Value on HTML 31K Recurring Basis (Detail) 37: R27 Fair Value Measurements - Additional Information HTML 22K (Detail) 38: R28 Potential Dilutive Shares Excluded from HTML 28K Computation of Diluted Net Loss Per Share (Detail) 39: R29 Net Loss per Share - Additional Information HTML 26K (Detail) 40: R30 Commitments and Contingencies - Additional HTML 303K Information (Detail) 41: R31 Related Party Transactions - Additional HTML 115K Information (Detail) 42: R32 Stock-Based Compensation Expense Included in HTML 25K Statement of Operations (Detail) 43: R33 Stock-Based Compensation - Additional Information HTML 40K (Detail) 44: R34 Fair Value of Stock Options Assumptions Using HTML 32K Black-Scholes Option Valuation Model (Detail) 45: R35 Stock Option Activity Under Stock Option Plan HTML 62K (Detail) 46: R36 Summary of Unvested Restricted Stock (Detail) HTML 42K 47: R37 Preferred Stock - Additional Information (Detail) HTML 54K 48: R38 Fair Values of Derivative Instruments to be HTML 23K classified as Derivative Liabilities on Balance Sheet (Detail) 49: R39 Change in Derivative Liability (Detail) HTML 25K 50: R40 Fair Value Assumptions Used in Probability HTML 29K Weighted Approach and Monte Carlo Simulation Model (Detail) 52: XML IDEA XML File -- Filing Summary XML 90K 51: EXCEL IDEA Workbook of Financial Reports XLSX 55K 5: EX-101.INS XBRL Instance -- ziop-20170630 XML 764K 7: EX-101.CAL XBRL Calculations -- ziop-20170630_cal XML 109K 8: EX-101.DEF XBRL Definitions -- ziop-20170630_def XML 487K 9: EX-101.LAB XBRL Labels -- ziop-20170630_lab XML 902K 10: EX-101.PRE XBRL Presentations -- ziop-20170630_pre XML 643K 6: EX-101.SCH XBRL Schema -- ziop-20170630 XSD 126K 53: ZIP XBRL Zipped Folder -- 0001193125-17-242331-xbrl Zip 110K
Download this zipped .zip folder | |
Files: | ziop-20170630.xml ziop-20170630.xsd ziop-20170630_cal.xml ziop-20170630_def.xml ziop-20170630_lab.xml ziop-20170630_pre.xml |